Table 1.
Characteristics of 559 men studied.
| Characteristic | HIV-infected (n = 328) | HIV-uninfected (n = 231) |
|---|---|---|
| Age** (mean years ± SD) | 54.7 ± 5 | 55.8 ± 5 |
| Race/ethnicity n (%) | ||
| Black | 200 (61) | 115 (50) |
| White | 39 (12) | 45 (19) |
| Hispanic | 77 (23) | 64 (28) |
| Unemployed* n (%) | 294 (90) | 180 (78) |
| Hypertension*** n (%) | 135 (41) | 122 (53) |
| Diabetes n (%) | 47 (14) | 36 (16) |
| Weight* (mean kg ± SD) | 77.7 ± 14 | 83.3 ± 15 |
| Body mass index* n (%) | ||
| < 25 kg/m2 (lean/normal) | 159 (48) | 70 (30) |
| 25−29.9 kg/m2 (overweight) | 121 (37) | 102 (44) |
| ≥ 30 kg/m2 (obese) | 48 (15) | 59 (26) |
| Moderate or strenuous exercise at least once/week n (%) | 159 (49) | 114 (49) |
| Ever used prednisone n (%) | 17 (5) | 5 (2) |
| Low testosterone (< 300 ng/dl) | 167 (51) | 135 (58) |
| Smoking*** n (%) | ||
| Never | 32 (10) | 23 (10) |
| Former | 95 (29) | 42 (18) |
| Current | 201 (61) | 166 (75) |
| Ever used drugs n (%) | 282 (86) | 216 (94) |
| Recent (past 5 years) heroin use* n (%) | 80 (24) | 87 (38) |
| Recent (past 5 years) cocaine or crack use*** n (%) | 163 (50) | 135 (58) |
| Current methadone treatment* n (%) | 124 (38) | 137 (59) |
| Bone mineral density, femoral neck (g/cm2)*** (mean ± SD) | 0.97 ± 0.14 | 1.00 ± 0.15 |
| Bone mineral density, lumbar spine (g/cm2) (mean ± SD) | 1.17 ± 0.20 | 1.20 ± 0.21 |
| T-score, femoral neck*** (mean ± SD) | −0.73 ± 1.09 | −0.53 ± 1.18 |
| T-score, lumbar spine (mean ± SD) | −0.60 ± 1.63 | −0.32 ± 1.73 |
| Length of HIV diagnosis n (%) | ||
| < 5 years | 46 (14) | |
| 5−10 years | 106 (33) | |
| > 10 years | 172 (53) | |
| Median CD4 cell count (cells/μl) (range) | 390 (3−2424) | |
| Ever protease inhibitor (PI) use n (%) | 244 (74) | |
| Median length of PI use (months) (range) | 24 (1−120) | |
| Ever nucleoside reverse transcriptase inhibitor (NRTI) n (%) | 294 (87) | |
| Median length of NRTI use (months) (range) | 36 (1−216) |
*
P ≤ 0.001
**
P ≤ 0.01
***
P ≤ 0.05.